Jacob Korach

6PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsRadiation therapyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 20, 2024
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.

Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri

|Apr 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.

Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega

|Mar 24, 2023
Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix.

Shira Peleg Hasson, Shira Felder, Limor Helpman

|Jul 06, 2022
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context.

Antonio González-Martín, Ursula A Matulonis, Jacob Korach

|Aug 02, 2019
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.

Jacob Korach, Nicoletta Colombo, Cesar Mendiola

|Jun 29, 2017
Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.

Limor Helpman, Omri Zidan, Eitan Friedman

Pageof 1

Frequent Collaborators

3 joint publications

Bradley J Monk

2 joint publications

Mansoor Raza Mirza

1 joint publications

Limor Helpman

1 joint publications

Omri Zidan